FTLD Treatment: Current Practice and Future Possibilities.
Adv Exp Med Biol
; 1281: 297-310, 2021.
Article
in En
| MEDLINE
| ID: mdl-33433882
ABSTRACT
While behavioral variant frontotemporal dementia (bvFTD) and primary progressive aphasia (PPA) remain unrelenting and universally fatal conditions, there is a framework for supportive treatment in patients diagnosed with these frontotemporal dementia (FTD) syndromes and the larger spectrum of clinical syndromes associated with frontotemporal lobar degeneration (FTLD) pathology on autopsy. A managing physician has an important role in weighing therapeutic options, organizing caregiver support, and framing long-term expectations for patients and caregivers. Additionally, a dedicated neurologist may assist patients and caregivers in navigating a growing range of FTD research, including exciting opportunities in clinical therapeutic trials. This chapter will review current therapeutic options for patients with bvFTD and PPA and detail the landscape of potential new disease-modifying therapies targeting the pathophysiology or FTLD.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pick Disease of the Brain
/
Frontotemporal Lobar Degeneration
/
Frontotemporal Dementia
Limits:
Humans
Language:
En
Journal:
Adv Exp Med Biol
Year:
2021
Document type:
Article
Affiliation country:
United States